Open access · CC-BY
via OpenAlex
Recovery from Rapamycin
Stephanie K. Evans, Karl E. Burgess, Joseph V. Gray
Journal of Biological Chemistry · 2014 · ▲ 16 citations
Abstract
The target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) complex 1 (TORC1) is a key conserved regulator of eukaryotic cell growth. The xenobiotic rapamycin is a potent inhibitor of the yeast complex. Surprisingly, the EGO complex, a nonessential in vivo activator of TORC1, is somehow required for yeast cells to recover efficiently from a period of treatment with rapamycin. Why? Here, we found that rapamycin is only a partial inhibitor of TORC1. We confirmed that saturating amounts of rapamycin do not fully inhibit proliferation of wild-type cells, and we found that the residual proliferation in the presence of the drug is dependent on the EGO complex and on the activity of TORC1. We found that this residual TORC1-dependent proliferation is key to recovery from rapamycin treatment. First, the residual proliferation rate correlates with the ability of cells to recover from treatment. Second, the residual proliferation rate persists long after washout of the drug and until cells recover. Third, the total observable pool of cell-associated rapamycin is extremely stable and decreases only with increasing cell number after washout of the drug. Finally, consideration of the residual proliferation rate alone accurately and quantitatively accounts for the kinetics of recovery of wild-type cells and for the nature and severity of the ego- mutant defect. Overall, our results revealed that rapamycin is a partial inhibitor of yeast TORC1, that persistence of the drug limits recovery, and that rapamycin is not detoxified by yeast but is passively diluted among progeny cells because of residual proliferation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1074/jbc.m114.589754
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Evans, S.K., Burgess, K.E., & Gray, J.V. (2014). Recovery from Rapamycin. <em>Journal of Biological Chemistry</em>. https://doi.org/10.1074/jbc.m114.589754
Vancouver
Evans SK, Burgess KE, Gray JV. Recovery from Rapamycin. Journal of Biological Chemistry. 2014. doi:10.1074/jbc.m114.589754.
BibTeX
@article{stephanie2014Recove,
title = {Recovery from Rapamycin},
author = {Stephanie K. Evans and Karl E. Burgess and Joseph V. Gray},
journal = {Journal of Biological Chemistry},
year = {2014},
doi = {10.1074/jbc.m114.589754},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2013
Open access · CC-BY
TORC 1 signaling inhibition by rapamycin and caffeine affect lifespan, global gene expression, and cell proliferation of fission yeast
Oncotarget 2017
Open access · CC-BY
Caloric restriction extends yeast chronological lifespan via a mechanism linking cellular aging to cell cycle regulation, maintenance of a quiescent state, entry into a non-quiescent state and survival in the non-quiescent state
Aging Cell 2023
Open access · CC-BY
Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
Molecular Cell 2019
Open access · CC-BY
Dual Role of Ribosome-Binding Domain of NAC as a Potent Suppressor of Protein Aggregation and Aging-Related Proteinopathies
Nature Immunology 2021
Citation only
Hallmarks of T cell aging
Aging 2020
Open access · OA